Cephalon Granted Temporary Restraining Order in AMRIX Patent Litigation

Today, the United States District Court for the District of Delaware granted a motion filed by plaintiffs Cephalon, Inc. CEPH, and Eurand, Inc., for a Temporary Restraining Order enjoining Mylan Pharmaceuticals Inc., and Mylan Inc. MYL, from manufacturing, using, offering to sell or selling its cyclobenzaprine hydrochloride extended-release capsules, a generic version of Cephalon's branded product AMRIX®. The TRO remains in effect pending appeal.